Logo image of BYSI

BEYONDSPRING INC (BYSI) Stock Fundamental Analysis

USA - NASDAQ:BYSI - KYG108301006 - Common Stock

1.7 USD
+0.02 (+1.19%)
Last: 9/26/2025, 11:43:49 AM
Fundamental Rating

1

Overall BYSI gets a fundamental rating of 1 out of 10. We evaluated BYSI against 538 industry peers in the Biotechnology industry. BYSI has a bad profitability rating. Also its financial health evaluation is rather negative. BYSI is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BYSI had negative earnings in the past year.
In the past 5 years BYSI always reported negative net income.
In the past 5 years BYSI always reported negative operating cash flow.
BYSI Yearly Net Income VS EBIT VS OCF VS FCFBYSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With a decent Return On Assets value of -35.83%, BYSI is doing good in the industry, outperforming 62.27% of the companies in the same industry.
Industry RankSector Rank
ROA -35.83%
ROE N/A
ROIC N/A
ROA(3y)-63.06%
ROA(5y)-63.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BYSI Yearly ROA, ROE, ROICBYSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BYSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BYSI Yearly Profit, Operating, Gross MarginsBYSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for BYSI has been increased compared to 1 year ago.
BYSI has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BYSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BYSI Yearly Shares OutstandingBYSI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
BYSI Yearly Total Debt VS Total AssetsBYSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

BYSI has an Altman-Z score of -17.98. This is a bad value and indicates that BYSI is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of BYSI (-17.98) is worse than 83.64% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.98
ROIC/WACCN/A
WACCN/A
BYSI Yearly LT Debt VS Equity VS FCFBYSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

BYSI has a Current Ratio of 2.19. This indicates that BYSI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.19, BYSI is doing worse than 72.86% of the companies in the same industry.
BYSI has a Quick Ratio of 2.19. This indicates that BYSI is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of BYSI (2.19) is worse than 71.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 2.19
BYSI Yearly Current Assets VS Current LiabilitesBYSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 49.06% over the past year.
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BYSI Yearly Revenue VS EstimatesBYSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2M 4M 6M 8M 10M
BYSI Yearly EPS VS EstimatesBYSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BYSI. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BYSI Price Earnings VS Forward Price EarningsBYSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BYSI Per share dataBYSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BYSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEYONDSPRING INC

NASDAQ:BYSI (9/26/2025, 11:43:49 AM)

1.7

+0.02 (+1.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-27 2025-03-27/amc
Earnings (Next)N/A N/A
Inst Owners14.41%
Inst Owner Change14.08%
Ins Owners15.26%
Ins Owner Change0%
Market Cap68.54M
Analysts85.71
Price TargetN/A
Short Float %6.24%
Short Ratio84.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.27
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.75
TBVpS-0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-63.06%
ROA(5y)-63.97%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.19
Quick Ratio 2.19
Altman-Z -17.98
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)42.12%
Cap/Depr(5y)971.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)49.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.9%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y41.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.19%
OCF growth 3YN/A
OCF growth 5YN/A